therapeutic action: reduction of depressive symptoms

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

mycolabadmin

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

Read More »

Psychedelic Psilocybin-Assisted Therapy Reduces Depressive Symptoms in Adults with Cancer and Depression

mycolabadmin

Researchers conducted a trial testing psilocybin-assisted therapy in cancer patients with depression. Participants received a single dose of psilocybin combined with therapy sessions. After eight weeks, most patients showed significant improvement in depression symptoms, with many achieving full remission. The treatment was generally safe with only mild side effects, and patients reported feeling more hopeful and better equipped to cope with their cancer diagnosis.

Read More »

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

mycolabadmin

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

Read More »
Scroll to Top